The title of the pharmaceutical company dropped more than 20% this December 6 at midday on Euronext Paris. In part, the partial suspension of clinical trials for one of his drug candidates. Our analysis and advice on the action Ipsen after this violent fall.

It’s a real cold shower for Ipsen . While the action of the pharmaceutical laboratory found for several weeks the favors of investors, it collapsed more than 20% this December 6 in the late morning.

This drop is due to the decision of the US Food and Drug Administration (FDA) to partially suspend three clinical studies of Ipsen evaluating its Palovarotene.